The luminal subtype of breast cancer, having both estrogen and progesterone receptors (ER/PR), is treated with hormonal therapy, which works by either blocking hormone synthetic pathways, disrupting the availability of natural hormones, or blocking cell surface hormone receptors [36]. Here, PGR is linked to breast cancer.